|Bid||0.00 x 1200|
|Ask||54.25 x 1200|
|Day's Range||53.43 - 54.81|
|52 Week Range||46.94 - 70.05|
|Beta (3Y Monthly)||1.37|
|PE Ratio (TTM)||240.31|
|Earnings Date||Feb 4, 2019 - Feb 8, 2019|
|Forward Dividend & Yield||1.60 (3.03%)|
|1y Target Est||59.88|
Many on Wall Street are weathering the autumn technology rout by buying the shares of firms with slower, steadier earnings growth, the latest sign that investors largely remain sanguine about U.S. stocks despite recent reversals. Trading has turned rocky since the S&P 500 finished the third quarter with its biggest gain since 2013. Nine years into the U.S. stock rally, investors are grappling with two forces.
Bristol-Myers' (BMY) immuno-oncology drug Opdivo combined with low-dose Yervoy gets positive opinion from CHMP for the treatment of intermediate- and poor-risk advanced RCC.
Is Paypal Holdings Inc (NASDAQ:PYPL) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, and get tips from industry insiders. They sometimes fail miserably but historically their consensus stock picks outperformed the market […]
FDA provides updates on Merck (MRK), AstraZeneca (AZN) and Roche (RHHBY) for their cancer drugs. Bayer (BAYRY) reports strong third-quarter results.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 15) Vapotherm, Inc. (NYSE: VAPO ) Down In The Dumps (Biotech ...
Recommendation based on results from the Phase 3 CheckMate -214 clinical trial
The FDA's Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee vote for Mallinckrodt (MNK) abuse-deterrent drug.
The biopharma giant, which came to Tampa in 2014 with fanfare, announced it will lay off 69 employees in January.
Exelixis (EXEL) and partner Ipsen receive EU approval for the label expansion of Cabometyx (cabozantinib) tablets as a monotherapy for HCC in adults.
Bristol-Myers Squibb (BMY) closed the most recent trading day at $52.61, moving +0.04% from the previous trading session.
NEW YORK, NY / ACCESSWIRE / November 13, 2018 / U.S. stocks closed down on Monday as oil prices continued to slide, raising concerns amongst investors. The Dow Jones Industrial Average plunged 2.32 percent ...
Nektar Therapeutics bounded higher Monday after its immunotherapy combination with Bristol-Myers Squibb showed promise as a melanoma treatment.
Nektar Therapeutics (NKTR) incurred general and administrative expenses of $18.72 million in the third quarter of 2018 as compared with $12.06 million in the third quarter of 2017. Nektar Therapeutics expects general and administrative expenses in fiscal 2018 to be higher than they were in fiscal 2017.
Nektar Therapeutics’ (NKTR) interest expense decreased marginally to $5.44 million in the third quarter of 2018 as compared with $5.54 million in the year-ago period. Its net interest and other income increased from $1.6 million in the third quarter of 2017 to $11.85 million in the third quarter of 2018 due to higher interest income from investments in debt securities that the company purchased with $1.85 billion it received from collaboration with Bristol-Myers Squibb (BMY) in April 2018. Nektar Therapeutics incurred a net loss of $96.14 million in the third quarter of 2018 as compared with net income of $60.87 million in the year-ago period.
Nektar Therapeutics’ (NKTR) non-cash royalty revenue associated with the sale of future royalties increased from $8.07 million in the third quarter of 2017 to $8.37 million in the third quarter of 2018. The significant drop in Nektar’s total revenues was attributable to a decline in license, collaboration, and other revenues, which decreased from $131.11 million in the third quarter of 2017 to $4.87 million in the third quarter of 2018.
According to Willie Delwiche, investment strategist at R.W. Baird, “Oil being down could be a sign that the global economy is in a tough spot.” “The initial reaction to lower oil prices has been that they’ll be a boon for the middle class,” Delwiche said that the view could be inaccurate considering that consumer confidence doesn’t have more chances to grow, and because a smaller part of the American consumer’s budget goes to gasoline than it has in the previous years. The stock recorded a trading volume of 1,456,948 shares, which was above its three months average volume of 998,535 shares. On Friday, shares of Bristol-Myers Squibb recorded a trading volume of 8,107,392 shares, which was above the three months average volume of 7,213,656 shares.
Repligen stock is on a rampage this year as it outperforms broad medical-products stocks. The bioprocessing firm has completely transformed, its CEO says.
Catalyst (CPRX) provides pipeline update and the FDA sets action date of Nov 28, 2018 for its lead pipeline candidate, Firdapse during the third quarter of 2018.
Keryx's (KERX) sole marketed product generates sales of $26.6 million in the third quarter, up 96% from the year-ago quarter.